Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M

Amylyx Pharmaceuticals, Inc.

2024-Q1 EPS reported -$1.75 revenue$88,643,000

Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.
Net product revenue $88.6M, up 24% YoY; includes $110.5M non-cash inventory write-down due to product withdrawal.
Voluntarily discontinuing RELYVRIO/ALBRIOZA for ALS; existing patients transitioned to free drug program.
Cash $373.3M, expected runway into 2026; interim HELIOS Wolfram data show improvement; topline from 12 patients expected fall 2024.
Phase 3 ORION PSP trial data expected mid-2025; IND and clinical trial of AMX0114 in ALS planned for H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.